CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Net product sales	$ 858,093	$ 44,686	$ 25,254
Sanofi collaboration revenue	423,814	326,609	311,332
Bayer HealthCare collaboration revenue	70,099	43,072	75,393
Technology licensing	23,571	24,858	40,150
Contract research and other	2,900	6,599	6,945
Total revenues	1,378,477	445,824	459,074
Expenses:
Research and development	625,554	529,506	489,252
Selling, general, and administrative	210,755	117,261	65,201
Cost of goods sold	84,455	4,216	2,093
Total expenses	920,764	650,983	556,546
Income (loss) from operations	457,713	(205,159)	(97,472)
Other income (expense):
Investment income	2,012	3,549	2,122
Interest expense	(45,304)	(21,282)	(9,118)
Total other income (expense)	(43,292)	(17,733)	(6,996)
Income (loss) before income taxes	414,421	(222,892)	(104,468)
Income tax benefit	335,848	1,132
Net income (loss)	750,269	(221,760)	(104,468)
Net income (loss) per share - basic (in dollars per share)	$ 7.92	$ (2.45)	$ (1.26)
Net income (loss) per share - diluted (in dollars per share)	$ 6.75	$ (2.45)	$ (1.26)
Weighted average shares outstanding - basic (in shares)	94,685	90,610	82,926
Weighted average shares outstanding - diluted (in shares)	115,382	90,610	82,926
Statements of Comprehensive Income (Loss)
Net income (loss)	750,269	(221,760)	(104,468)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax	696	629	(3,535)
Comprehensive income (loss)	$ 750,965	$ (221,131)	$ (108,003)